The World Health Organization warned that fighting in Sudan brings a “huge biological risk” as a lab holding samples of deadly diseases is occupied. Fighters “kicked out all the technicians from the lab… which is completely under the control of one of the fighting parties as a military base,” said Nima Saeed Abid, the WHO’s representative in Sudan. (CBS News)
Danaher cut its annual sales growth forecast on biotech funding woes. Danaher’s biotechnology business helps companies to manufacture biological medicines, but it has been facing pressures due to a funding crunch in the sector over the last one year. (Reuters)
Ideaya Biosciences has plans to move ahead with an initial public offering of up to $150 million. This comes days after the biotech released promising interim results from its Phase II clinical trial investigating a combination of darovasertib and crizotinib to treat metastatic uveal melanoma. (Endpoint News)
Arbutus announced that the Food and Drug Administration has placed a clinical hold on its IND application for AB-101. The study hold placed on the company’s oral PD-L1 inhibitor caused its stock price to slide. (MarketWatch)
Bank of America downgraded Day One Biopharmaceuticals to an Underperform rating. The company previously had a Buy rating and a price target of $34, but now has a price target of $9. (Seeking Alpha)
